Becton, Dickinson and Co. Fourth Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Becton, Dickinson and Co. (NYSE:BDX) will unveil its latest earnings on Wednesday, November 2, 2011. Becton, Dickinson & Company provides healthcare institutions, life science researchers, clinical laboratories, and individual consumers with laboratory equipment, medical supplies, devices, and diagnostic products.

Becton, Dickinson and Co. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of $1.39 per share, a rise of 12.1% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.46. Between one and three months ago, the average estimate moved down. It has been unchanged at $1.39 during the last month. For the year, analysts are projecting profit of $5.64 per share, a rise of 15.1% from last year.

Past Earnings Performance: The company’s quarterly results have come in above estimates for the last three quarters. Last quarter, the company booked net income of $1.51 per share versus a mean estimate of profit of $1.43 per share.

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

Wall St. Revenue Expectations: On average, analysts predict $2.02 billion in revenue this quarter, a rise of 8% from the year ago quarter. Analysts are forecasting total revenue of $7.8 billion for the year, a rise of 5.8% from last year’s revenue of $7.37 billion.

Analyst Ratings: Analysts seem relatively indifferent about Becton, Dickinson and with 11 of 18 analysts surveyed maintaining a hold rating.

A Look Back: In the third quarter, profit rose 11.8% to $343.1 million ($1.53 a share) from $306.9 million ($1.29 a share) the year earlier, exceeding analyst expectations. Revenue rose 7.2% to $2.01 billion from $1.88 billion.

Key Stats:

The company has seen net income rise in two straight quarters. In the second quarter, profit rose 4.8%.

The company’s revenue has risen for two straight quarters. In the second quarter, the figure rose 4.2%.

Competitors to Watch: Covidien plc (NYSE:COV), Thermo Fisher Scientific Inc. (NYSE:TMO), C.R. Bard, Inc. (NYSE:BCR), Teleflex Incorporated (NYSE:TFX), Retractable Tech., Inc. (AMEX:RVP), Hologic, Inc. (NASDAQ:HOLX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Medical Action Industries (NASDAQ:MDCI), Quidel Corporation (NASDAQ:QDEL), and Gen-Probe Incorporated (NASDAQ:GPRO).

Stock Price Performance: During September 29, 2011 to October 27, 2011, the stock price had risen $4.33 (5.8%) from $74.34 to $78.67. The stock price saw one of its best stretches over the last year between December 6, 2010 and December 14, 2010 when shares rose for seven-straight days, rising 3.7% (+$2.90) over that span. It saw one of its worst periods between September 15, 2011 and September 22, 2011 when shares fell for six-straight days, falling 5.3% (-$4.10) over that span. Shares are down $4.57 (-5.5%) year to date.

(Source: Xignite Financials)

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.